**Neocate® Syneo® Infant helps balance the gut microbiota to be closer to that of healthy, breastfed infants**

A multicenter, prospective, randomized, double-blind controlled study in CMA

**METHOD:**

**OUTCOME AFTER 8 WEEKS:**

**Primary outcomes:**
- Bifidobacteria as a marker of a balanced infant gut microbiota
- The *Eubacterium rectale/Clostridium coccoides* group representing a more adult-like gut bacterial group

**Results:**
- Higher levels of fecal bifidobacteria and lower levels of fecal clostridia + eubacteria were observed with Neocate Syneo Infant, bringing the gut microbiota closer to that of healthy breastfed infants (vs. a standard AAF without the Syneo blend (p<0.001))

**Consistent effect seen after 8, 12, and 26 weeks**

**REFERENCES:**

*Infants after 8 weeks of management with standard amino acid-based formula (control) or amino acid-based formula with pre- and probiotics (test) compared to age-matched, healthy, breastfed infants. At 8 weeks, levels of both bifidobacteria and *Eubacterium rectale* + *Clostridium coccoides* group were measured as a percentage of total fecal bacteria. Test group median levels were different than control group (p=0.001), and were closer to breastfed infant levels vs. control group.

**EXTENDED CLINICAL DATA**

Nutricia North America supports the use of breast milk wherever possible. Neocate® is a family of hypoallergenic, amino acid-based medical foods. Neocate is intended for use under medical supervision. Neocate Syneo Infant is indicated for the dietary management of cow milk allergy, multiple food allergies and related GI and allergic conditions, including food protein-induced enterocolitis syndrome, eosinophilic esophagitis and gastroesophageal reflux.

©2019 Nutricia North America